Dr. Thomas is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1441 Eastlake Ave
Los Angeles, CA 90089Phone+1 323-865-3105
Education & Training
University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2015 - 2018
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2012 - 2015
University of Illinois College of MedicineClass of 2012
Certifications & Licensure
CA State Medical License 2014 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors Start of enrollment: 2018 Aug 21
Publications & Presentations
PubMed
- 19 citationsMolecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases.Gino K. In, Kelsey Poorman, Michelle Saul, Steven J. O'Day, Jeffrey M. Farma
Oncotarget. 2020-08-18 - 1 citationsComplete response with pembrolizumab in recurrent squamous cell carcinoma of the oral tongue: A case report.Jocelyn Y Cheng, Robert C Hsu, Jorge J Nieva, Jacob S Thomas
Oral Oncology. 2023-12-01 - Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma.Alexandra Jackovich, Barbara J Gitlitz, Justin Wayne Wong Tiu-Lim, Vinay Duddalwar, Kevin George King
Oncotarget. 2024-07-10
Press Mentions
Intensity Therapeutics Reports Promising Overall Survival Results Using INT230-6 as a Monotherapy or in Combination with Pembrolizumab or Ipilimumab to Treat Solid Tumors, at the Society for Immunotherapy of Cancer's (SITC) 36th Annual MeetingNovember 13th, 2021
Data from Intensity Therapeutics’ Phase 1/2 Study of INT230-6 Highlight Prolonged Disease Control, Abscopal Effects and Immune Response Activity in Patients with Advanced Solid TumorsNovember 7th, 2019
Hoag Hospital Clinical Investigator Discusses the Importance of Clinical Trials in the CommunityAugust 30th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
